Cefepime–taniborbactam and ceftibuten–ledaborbactam maintain activity against KPC variants that lead to ceftazidime–avibactam resistance

Abstract excerpt

ABSTRACT Klebsiella pneumoniae carbapenemases (KPCs) are widespread β-lactamases that are a major cause of clinical non-susceptibility of Gram-negative bacteria to carbapenems and other β-lactam antibiotics. Ceftazidime combined with the β-lactamase inhibitor avibactam (CAZ–AVI) has been effective in treating infections by KPC-producing bacteria, but emerging KPC variants confer resistance to the combination....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibiotic Resistance in Bacteria
• Share to Antibiotics Pharmacokinetics and Efficacy
• Share to Escherichia coli research studies